Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis

BACKGROUND: Experience with immune checkpoint inhibitors (ICIs) in the treatment of acute myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported randomized clinical data. In this study, we reviewed the available evidence on the use of ICIs, either in monotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Llobell, Marina, Peleteiro Raíndo, Andrés, Climent Medina, Jose, Gómez Centurión, Ignacio, Mosquera Orgueira, Adrián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069679/
https://www.ncbi.nlm.nih.gov/pubmed/35530329
http://dx.doi.org/10.3389/fonc.2022.882531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069679/
https://www.ncbi.nlm.nih.gov/pubmed/35530329
http://dx.doi.org/10.3389/fonc.2022.882531

Ejemplares similares